Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129178 | 0.86 | NR1H2 (0.37) | NR1H2RECQLUSP2SMN1; SMN2PRMT5 | |
| SCHEMBL20129177 | 0.86 | NR1H2 (0.40) | NR1H2RECQLUSP2SMN1; SMN2PRMT5 | |
| SCHEMBL20129039 | 0.86 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3RECQL | |
| SCHEMBL20233783 | 0.84 | NR1H2 (0.34) | NR1H2RECQLUSP2SMN1; SMN2PRMT5 | |
| SCHEMBL27098084 | 0.78 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3PRMT5 | |
| SCHEMBL27098040 | 0.78 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3PRMT5 | |
| SCHEMBL20129033 | 0.77 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3RECQL | |
| SCHEMBL20129207 | 0.76 | NR1H2 (0.43) | NR1H2RECQLUSP2SMN1; SMN2PRMT5 | |
| SCHEMBL30229991 | 0.76 | — | — | |
| SCHEMBL27097888 | 0.75 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | NR1H2 3751/4885CHRM2 4590/4885CHRM1 4568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.